Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD1 | P21728 | 4/20 | 0.44 |
| ▸ | DRD4 | P21917 | 3/20 | 0.42 |
| ▸ | PNMT | P11086 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 4/20 | 0.40 |
| ▸ | DRD5 | P21918 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30015222 | 0.98 | DRD2 (0.46) | DRD2DRD1DRD4PNMTDRD3 | |
| SCHEMBL329946 | 0.98 | DRD2 (0.46) | DRD2DRD1DRD4PNMTDRD3 | |
| Hydrochloric Acid SCHEMBL3772707 | 0.95 | DRD2 (0.44) | DRD2DRD1DRD4PNMTDRD3 | |
| Bromide SCHEMBL6190676 | 0.83 | PNMT (0.63) | DRD2DRD1DRD4PNMTDRD3 | |
| Bromide SCHEMBL587893 | 0.83 | DRD2 (0.61) | DRD2DRD1DRD4PNMTDRD3 | |
| SCHEMBL29514775 | 0.80 | DRD2 (0.62) | DRD2DRD1DRD4PNMTDRD3 | |
| SCHEMBL470826 | 0.80 | PNMT (0.66) | DRD2DRD1DRD4PNMTDRD3 | |
| SCHEMBL1017452 | 0.80 | DRD2 (0.62) | DRD2DRD1DRD4PNMTDRD3 | |
| Bromide SCHEMBL1648391 | 0.80 | DRD2 (0.59) | DRD2DRD1DRD4PNMTDRD3 | |
| Bromide SCHEMBL6071099 | 0.80 | DRD2 (0.59) | DRD2DRD1DRD4PNMTDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260092076-A1 | NOVEL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2026-04-02 | — | — | US | disclosed |
| US-12371421-B2 | Solid forms of a PARP7 inhibitor | RIBON THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250074897-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20250020654-A1 | SCREENING METHODS FOR PARP MODULATORS | RIBON THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| US-20240190844-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2024-02-01 | — | — | US | disclosed |
| EP-3623369-B1 | NOVEL MORPHOLINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-10-25 | — | — | EP | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-6521638-B1 | Such as 2-(2-(1-(4-(3-(3-methanesulfonyl)phenylpropenoyl)-amino)cyclohexyl)ethyl) -2,3-dihydro-1H-isoindole; amidation of amine and carbonyl halide | SMITHKLINE BEECHAM P.L.C. (DE) | 2003-02-18 | — | — | US | disclosed |
| US-6348478-B1 | BLOOD COAGULATION FACTORS AND ANTICOAGULANTS | TEIJIN LIMITED (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1119562-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| EP-1043311-A1 | BIPHENYLAMIDINE DERIVATIVES | TEIJIN LIMITED (JP) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000021950-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-20 | — | — | WO | disclosed |
| EP-0452987-B1 | Isoindoline derivatives | BANYU PHARMA CO LTD (JP) | 1995-03-01 | — | — | EP | disclosed |
| EP-0186187-B1 | CEPHALOSPORIN DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1992-02-26 | — | — | EP | disclosed |
| EP-0452987-A1 | Isoindoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-23 | — | — | EP | disclosed |
| US-4677100-A | ANTIBIOTICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-06-30 | — | — | US | disclosed |
| EP-0186187-A2 | Cephalosporin derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190844-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | DRD2 3772/4885DRD1 4165/4885DRD4 3518/4885 |
| US-12371421-B2 | Solid forms of a PARP7 inhibitor | PARP1, PARP2, PARP4 | DRD2 4232/4885DRD1 4234/4885DRD4 3987/4885 |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | DRD2 3772/4885DRD1 4165/4885DRD4 3518/4885 |
| US-20250074897-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | DRD2 3772/4885DRD1 4165/4885DRD4 3518/4885 |
| US-12617782-B2 | Pyridazinones as PARP7 inhibitors | PARP3, PARP2, PARP1 | DRD2 1959/4885DRD1 2663/4885DRD4 3327/4885 |
| US-20250020654-A1 | SCREENING METHODS FOR PARP MODULATORS | PARP1, PARP2, PARP3 | DRD2 4282/4885DRD1 4608/4885DRD4 4296/4885 |
| US-20260092076-A1 | NOVEL COMPOUNDS | NOD1, NLRP3, ARRB1 | DRD2 2665/4885DRD1 3116/4885DRD4 3556/4885 |
| US-20240034728-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | DRD2 3772/4885DRD1 4165/4885DRD4 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.